Drug recall
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60…
FDA recall event 84671 · Class II · Preferred Pharmaceuticals, Inc
Key facts
| Event ID | 84671 |
|---|---|
| Recall numbers | D-0796-2020, D-0797-2020 |
| Recalling firm | Preferred Pharmaceuticals, Inc |
| Product type | Drugs |
| Products | Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count…, Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 count bottles (NDC: 68788-6382-1), b) 30 count bottles (NDC: 68788-6382-3), c) 90 count bottles (NDC: 68788-6382-9), d) 100… |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm Initiated |
| Reason for recall | CGMP Deviations: Presence of NDMA impurity detected in product. |
| Initiation date | Jan 7, 2020 |
| Report date | Jan 29, 2020 |
| Termination date | Dec 14, 2023 |
| City | Anaheim |
| State | CA |
| Country | United States |
| FEI number | 3004582966 |
At a glance
- 1–9 Products in this recall
- 1–9 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports · Source date: